Tech startups such as Thrive Holdings, daydream, Syneron Bio, among others, have announced their venture capital funding to bolster innovation and business growth.
Thrive Holdings Secures Up to $2 bn
Thrive Holdings, backed by Thrive Capital, is raising up to $2 billion in venture funding to expand its AI-driven platform focused on transforming traditional industries such as IT and accounting. The initiative combines roll-up strategy with AI deployment to modernize operations using automation, analytics, and intelligent workflows. The funding includes approximately $1 billion in initial commitments from venture investors. Strategically, the partnership enables large-scale deployment of AI across legacy service sectors, improving productivity and scalability. The investment reflects strong demand for AI-led transformation platforms and positions Thrive as a major player in enterprise AI services.
daydream Raises $15 mn
daydream, an AI-native SEO and search optimization platform, raised $15 million in Series A funding led by WndrCo, with participation from First Round Capital and Basis Set Ventures. Founded by Thenuka Karunaratne, the company builds AI agents to automate enterprise SEO strategy and execution. The funding brings total capital raised to $21 million and will be used for product development, hiring, and go-to-market expansion. Strategically, the partnership enables rapid deployment of AI-driven marketing automation. The collaboration strengthens daydream’s ability to scale AI-native SaaS infrastructure and redefine enterprise search optimization through intelligent automation.
Syneron Bio Raises $150 mn
Syneron Bio raised $150 million in Series B funding from a consortium of venture capital investors and strategic backers to advance its AI-enabled drug discovery platform. The company focuses on macrocyclic peptide therapeutics using computational biology and automation technologies. Founded by a team of biotech and AI experts, Syneron leverages machine learning to accelerate precision medicine development. The funding supports platform scaling, R&D expansion, and clinical pipeline advancement. Strategically, the partnership enables deployment of next-generation AI in life sciences, strengthening innovation in biotech and positioning the company as a leader in intelligent drug discovery systems.
THASNIYA VP
